
Warning Letter
Warning Letter
In a 7 January
As is typical in these warnings, the agency voicedconcerns that Essential is compounding not for individual patients butfor third-party resale, and that the compounded drugs duplicateapproved products in dosage and concentration.
Douglas McCormick
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





